Published in Am J Epidemiol on April 24, 2009
Association of overactive bladder and C-reactive protein levels. Results from the Boston Area Community Health (BACH) Survey. BJU Int (2011) 1.50
Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol (2010) 1.11
Effect of high-dose intravenous vitamin C on inflammation in cancer patients. J Transl Med (2012) 1.09
Association between systemic inflammatory markers and serum prostate-specific antigen in men without prostatic disease - the 2001-2008 National Health and Nutrition Examination Survey. Prostate (2014) 1.01
The link between benign prostatic hyperplasia and prostate cancer. Nat Rev Urol (2012) 0.98
Clinical experience with intravenous administration of ascorbic acid: achievable levels in blood for different states of inflammation and disease in cancer patients. J Transl Med (2013) 0.90
The role of serum C-reactive protein in women with lower urinary tract symptoms. Int Urogynecol J (2012) 0.88
Nonsteroidal antiinflammatory drug use and lower urinary tract symptoms: results from the Boston area community health survey. Am J Epidemiol (2011) 0.86
Dietary macronutrient and energy intake and urinary incontinence in women. Am J Epidemiol (2010) 0.86
Effect of sexually transmitted infections, lifetime sexual partner count, and recreational drug use on lower urinary tract symptoms in men who have sex with men. Urology (2011) 0.85
Increased serum C-reactive protein level is associated with increased storage lower urinary tract symptoms in men with benign prostatic hyperplasia. PLoS One (2014) 0.85
Invited commentary: Lower urinary tract symptoms and inflammation--weighing the evidence. Am J Epidemiol (2009) 0.85
Lower urinary tract symptoms and diet quality: findings from the 2000-2001 National Health and Nutrition Examination Survey. Urology (2012) 0.82
Dietary macronutrient intake and lower urinary tract symptoms in women. Ann Epidemiol (2011) 0.79
Lower Urinary Tract Symptoms, Depression, Anxiety and Systemic Inflammatory Factors in Men: A Population-Based Cohort Study. PLoS One (2015) 0.78
Lower urinary tract symptoms among Caucasian-European men who have sex with men: findings from a real-life survey. Prostate Cancer Prostatic Dis (2015) 0.75
Is high-sensitivity C-reactive protein associated with lower urinary tract symptoms in aging men? Results from the hallym aging study. Korean J Urol (2012) 0.75
Association of variants in genes related to the immune response and obesity with BPH in CLUE II. Prostate Cancer Prostatic Dis (2014) 0.75
Association between PSA Levels and Biomarkers of Subclinical Systemic Inflammation in Middle-Aged Healthy Men from the General Population. Curr Urol (2016) 0.75
Genetic Determinants of Metabolism and Benign Prostate Enlargement: Associations with Prostate Volume. PLoS One (2015) 0.75
Molecular pathogenesis of human prostate basal cell hyperplasia. Prostate (2017) 0.75
Random-effects models for longitudinal data. Biometrics (1982) 54.17
The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol (1992) 13.63
C-reactive protein: a critical update. J Clin Invest (2003) 11.77
Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA (1993) 5.77
The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol (1993) 3.66
C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ (1996) 3.61
Natural history of prostatism: risk factors for acute urinary retention. J Urol (1997) 3.59
Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol (2003) 2.17
What does minor elevation of C-reactive protein signify? Am J Med (2006) 2.14
Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis (1998) 1.95
The effect of weight loss on C-reactive protein: a systematic review. Arch Intern Med (2007) 1.84
Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol (1995) 1.75
Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol (1996) 1.73
Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial. J Urol (2007) 1.69
Validation of a new quality of life questionnaire for benign prostatic hyperplasia. J Clin Epidemiol (1992) 1.65
Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol (1999) 1.53
Families of lines: random effects in linear regression analysis. J Appl Physiol (1985) (1988) 1.48
Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study. J Urol (1979) 1.44
Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press (1999) 1.40
Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int (2007) 1.40
Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation. J Urol (2002) 1.40
The long-term relationship between a real change in prostate volume and a significant change in lower urinary tract symptom severity in population-based men: the Krimpen study. Eur Urol (2007) 1.39
Obesity and C-reactive protein levels among white, black, and hispanic US adults. Obesity (Silver Spring) (2008) 1.38
Longitudinal changes in peak urinary flow rates in a community based cohort. J Urol (2000) 1.34
Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate (2005) 1.34
Risk of type 2 diabetes attributable to C-reactive protein and other risk factors. Diabetes Care (2007) 1.34
Associations between diabetes and clinical markers of benign prostatic hyperplasia among community-dwelling Black and White men. Diabetes Care (2007) 1.32
Natural history of prostatism: factors associated with discordance between frequency and bother of urinary symptoms. Urology (1993) 1.27
Relationship between prostate specific antigen, prostate volume and age in the benign prostate. Br J Urol (1993) 1.26
Interrelationships between inflammation, C-reactive protein, and insulin resistance. J Cardiometab Syndr (2006) 1.20
Tracking of longitudinal changes in measures of benign prostatic hyperplasia in a population based cohort. J Urol (2006) 1.19
Do prostate size and urinary flow rates predict health care-seeking behavior for urinary symptoms in men? Urology (1995) 1.15
Diabetes and benign prostatic hyperplasia progression in Olmsted County, Minnesota. Urology (2006) 1.13
Insulin-like growth factor I, insulin-like growth factor binding protein 3, and urologic measures of benign prostatic hyperplasia. Am J Epidemiol (2003) 1.06
Inflammatory Mechanisms Associated with Prostatic Inflammation and Lower Urinary Tract Symptoms. Curr Prostate Rep (2008) 1.02
Serum C-reactive protein is an independent risk factor predicting cardiometabolic risk. Metabolism (2008) 0.99
Do prostatic infarction, prostatic inflammation and prostate morphology play a role in acute urinary retention? Eur Urol (2005) 0.98
Correlations between longitudinal changes in transitional zone volume and measures of benign prostatic hyperplasia in a population-based cohort. Eur Urol (2006) 0.97
Parameters of prostate volume and shape in a community based population of men 55 to 74 years old. J Urol (1994) 0.96
Relation between acute urinary retention, chronic prostatic inflammation and accompanying elevated prostate-specific antigen. Scand J Urol Nephrol (2006) 0.92
C-reactive protein in hypertension: clinical significance and predictive value. Nutr Metab Cardiovasc Dis (2006) 0.88
Illustrating the roles of C-reactive protein in the development of the metabolic syndrome in women--a cross-racial validation. Nutr Metab Cardiovasc Dis (2008) 0.83
Association of C-reactive protein, interleukin-1 receptor antagonist and adiponectin with the metabolic syndrome. Mediators Inflamm (2007) 0.83
The influence of finasteride on the development of prostate cancer. N Engl J Med (2003) 24.45
Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med (2006) 17.13
Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA (2003) 13.79
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med (2004) 11.52
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol (2004) 8.97
Trends in heart failure incidence and survival in a community-based population. JAMA (2004) 8.90
DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med (2006) 7.90
Plasma adiponectin levels and risk of myocardial infarction in men. JAMA (2004) 7.46
Systolic and diastolic heart failure in the community. JAMA (2006) 5.99
The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care (2005) 4.38
Urologic diseases in America project: benign prostatic hyperplasia. J Urol (2005) 4.09
Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation (2005) 3.85
American Urological Association guideline on the management of priapism. J Urol (2003) 3.77
Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol (2002) 3.68
The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med (2011) 3.68
Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. JAMA (2002) 3.44
Why patients visit their doctors: assessing the most prevalent conditions in a defined American population. Mayo Clin Proc (2013) 3.40
Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation (2005) 3.34
Differential adoption of laser prostatectomy for treatment of benign prostatic hyperplasia. Urology (2013) 3.31
Genetic variants at 2q24 are associated with susceptibility to type 2 diabetes. Hum Mol Genet (2010) 3.24
Agreement between patient-reported symptoms and their documentation in the medical record. Am J Manag Care (2008) 3.08
The association between statin use and the diagnosis of prostate cancer in a population based cohort. J Urol (2010) 3.08
Trends in incidence, severity, and outcome of hospitalized myocardial infarction. Circulation (2010) 3.07
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst (2005) 2.99
Increased risk of serious pneumococcal disease in patients with asthma. J Allergy Clin Immunol (2008) 2.97
Trends in the incidence and survival of patients with hospitalized myocardial infarction, Olmsted County, Minnesota, 1979 to 1994. Ann Intern Med (2002) 2.87
Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA (2011) 2.86
Effect of age on the risk of Fever and seizures following immunization with measles-containing vaccines in children. JAMA Pediatr (2013) 2.86
Redefinition of myocardial infarction: prospective evaluation in the community. Circulation (2006) 2.76
The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum (2005) 2.74
Stratifying risk of urinary tract malignant tumors in patients with asymptomatic microscopic hematuria. Mayo Clin Proc (2013) 2.72
Agreement between patient reports of cardiovascular disease and patient medical records. Mayo Clin Proc (2005) 2.71
Diastolic dysfunction and left atrial volume: a population-based study. J Am Coll Cardiol (2005) 2.69
Left atrial volume as an index of left atrial size: a population-based study. J Am Coll Cardiol (2003) 2.62
Heart failure and death after myocardial infarction in the community: the emerging role of mitral regurgitation. Circulation (2005) 2.61
Two common chromosome 8q24 variants are associated with increased risk for prostate cancer. Cancer Res (2007) 2.56
Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. Perm J (2012) 2.55
Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA (2011) 2.54
Cardiac rehabilitation after myocardial infarction in the community. J Am Coll Cardiol (2004) 2.52
How common is attention-deficit/hyperactivity disorder? Incidence in a population-based birth cohort in Rochester, Minn. Arch Pediatr Adolesc Med (2002) 2.51
Prevalence of extreme obesity in a multiethnic cohort of children and adolescents. J Pediatr (2010) 2.46
Correlates for human papillomavirus vaccination of adolescent girls and young women in a managed care organization. Am J Epidemiol (2010) 2.42
Urologic diseases in america project: benign prostatic hyperplasia. J Urol (2008) 2.38
Teaching and learning responsible research conduct: influences of prior experiences on acceptance of new ideas. Account Res (2008) 2.38
Limitations of estimating glomerular filtration rate from serum creatinine in the general population. Mayo Clin Proc (2006) 2.37
Long-term school outcomes for children with attention-deficit/hyperactivity disorder: a population-based perspective. J Dev Behav Pediatr (2007) 2.36
Coronary heart disease death and sudden cardiac death: a 20-year population-based study. Am J Epidemiol (2003) 2.34
Pneumococcal vaccination and risk of acute myocardial infarction and stroke in men. JAMA (2010) 2.30
Secular trends in deaths from cardiovascular diseases: a 25-year community study. Circulation (2006) 2.24
The effect of benign lower urinary tract symptoms on subsequent prostate cancer testing and diagnosis. Eur Urol (2013) 2.19
Phosphorus and risk of renal failure in subjects with normal renal function. Am J Med (2013) 2.18
Electronic medical records for clinical research: application to the identification of heart failure. Am J Manag Care (2007) 2.18
Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med (2006) 2.09
Coronary disease surveillance in Olmsted County objectives and methodology. J Clin Epidemiol (2002) 2.06
A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc (2002) 2.04
Papanicolaou screening behavior in mothers and human papillomavirus vaccine uptake in adolescent girls. Am J Public Health (2009) 2.03
Population-based prevalence of repeated group A beta-hemolytic streptococcal pharyngitis episodes. Mayo Clin Proc (2006) 2.03
Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine. Vaccine (2011) 2.03
Incidence of heart failure after myocardial infarction: is it changing over time? Am J Epidemiol (2003) 2.03
A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res (2005) 2.02
Scores for post-myocardial infarction risk stratification in the community. Circulation (2002) 1.98
A population-based, longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc (2009) 1.98
Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol (2006) 1.98
The incidence of autism in Olmsted County, Minnesota, 1976-1997: results from a population-based study. Arch Pediatr Adolesc Med (2005) 1.97
Correlates for completion of 3-dose regimen of HPV vaccine in female members of a managed care organization. Mayo Clin Proc (2009) 1.96
Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev (2007) 1.94
Genetic variants in ABO blood group region, plasma soluble E-selectin levels and risk of type 2 diabetes. Hum Mol Genet (2010) 1.89
Best practice policies for male infertility. Fertil Steril (2002) 1.88
Temporal trends in the incidence of coronary disease. Am J Med (2004) 1.86
Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol (2003) 1.83
Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol (2005) 1.83
Math learning disorder: incidence in a population-based birth cohort, 1976-82, Rochester, Minn. Ambul Pediatr (2005) 1.83
Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care (2005) 1.81
Priapism: pathogenesis, epidemiology, and management. J Sex Med (2010) 1.79
Heart failure after myocardial infarction: a review. Am J Med (2002) 1.76
Seasonality and daily weather conditions in relation to myocardial infarction and sudden cardiac death in Olmsted County, Minnesota, 1979 to 2002. J Am Coll Cardiol (2006) 1.73